List of Tables
Table 1. Global Neuromyelitis Optic Spectrum Disorder Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Neuromyelitis Optic Spectrum Disorder Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Neuromyelitis Optic Spectrum Disorder Drugs Market Competitive Situation by Manufacturers in 2024
Table 4. Global Neuromyelitis Optic Spectrum Disorder Drugs Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Neuromyelitis Optic Spectrum Disorder Drugs Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Neuromyelitis Optic Spectrum Disorder Drugs Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Neuromyelitis Optic Spectrum Disorder Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Neuromyelitis Optic Spectrum Disorder Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Neuromyelitis Optic Spectrum Disorder Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Neuromyelitis Optic Spectrum Disorder Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Neuromyelitis Optic Spectrum Disorder Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optic Spectrum Disorder Drugs as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Neuromyelitis Optic Spectrum Disorder Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Neuromyelitis Optic Spectrum Disorder Drugs Sales by Region (2020-2025) & (K Units)
Table 18. Global Neuromyelitis Optic Spectrum Disorder Drugs Sales Market Share by Region (2020-2025)
Table 19. Global Neuromyelitis Optic Spectrum Disorder Drugs Sales by Region (2026-2031) & (K Units)
Table 20. Global Neuromyelitis Optic Spectrum Disorder Drugs Sales Market Share by Region (2026-2031)
Table 21. Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue Market Share by Region (2020-2025)
Table 23. Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue Market Share by Region (2026-2031)
Table 25. North America Neuromyelitis Optic Spectrum Disorder Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Neuromyelitis Optic Spectrum Disorder Drugs Sales by Country (2020-2025) & (K Units)
Table 27. North America Neuromyelitis Optic Spectrum Disorder Drugs Sales by Country (2026-2031) & (K Units)
Table 28. North America Neuromyelitis Optic Spectrum Disorder Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Neuromyelitis Optic Spectrum Disorder Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Neuromyelitis Optic Spectrum Disorder Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Neuromyelitis Optic Spectrum Disorder Drugs Sales by Country (2020-2025) & (K Units)
Table 32. Europe Neuromyelitis Optic Spectrum Disorder Drugs Sales by Country (2026-2031) & (K Units)
Table 33. Europe Neuromyelitis Optic Spectrum Disorder Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Neuromyelitis Optic Spectrum Disorder Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Neuromyelitis Optic Spectrum Disorder Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Neuromyelitis Optic Spectrum Disorder Drugs Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Neuromyelitis Optic Spectrum Disorder Drugs Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Neuromyelitis Optic Spectrum Disorder Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Neuromyelitis Optic Spectrum Disorder Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Neuromyelitis Optic Spectrum Disorder Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Neuromyelitis Optic Spectrum Disorder Drugs Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Neuromyelitis Optic Spectrum Disorder Drugs Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Neuromyelitis Optic Spectrum Disorder Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Neuromyelitis Optic Spectrum Disorder Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Neuromyelitis Optic Spectrum Disorder Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Neuromyelitis Optic Spectrum Disorder Drugs Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Neuromyelitis Optic Spectrum Disorder Drugs Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Neuromyelitis Optic Spectrum Disorder Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Neuromyelitis Optic Spectrum Disorder Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Neuromyelitis Optic Spectrum Disorder Drugs Sales (K Units) by Type (2020-2025)
Table 51. Global Neuromyelitis Optic Spectrum Disorder Drugs Sales (K Units) by Type (2026-2031)
Table 52. Global Neuromyelitis Optic Spectrum Disorder Drugs Sales Market Share by Type (2020-2025)
Table 53. Global Neuromyelitis Optic Spectrum Disorder Drugs Sales Market Share by Type (2026-2031)
Table 54. Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue Market Share by Type (2020-2025)
Table 57. Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue Market Share by Type (2026-2031)
Table 58. Global Neuromyelitis Optic Spectrum Disorder Drugs Price (US$/Unit) by Type (2020-2025)
Table 59. Global Neuromyelitis Optic Spectrum Disorder Drugs Price (US$/Unit) by Type (2026-2031)
Table 60. Global Neuromyelitis Optic Spectrum Disorder Drugs Sales (K Units) by Application (2020-2025)
Table 61. Global Neuromyelitis Optic Spectrum Disorder Drugs Sales (K Units) by Application (2026-2031)
Table 62. Global Neuromyelitis Optic Spectrum Disorder Drugs Sales Market Share by Application (2020-2025)
Table 63. Global Neuromyelitis Optic Spectrum Disorder Drugs Sales Market Share by Application (2026-2031)
Table 64. Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue Market Share by Application (2020-2025)
Table 67. Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue Market Share by Application (2026-2031)
Table 68. Global Neuromyelitis Optic Spectrum Disorder Drugs Price (US$/Unit) by Application (2020-2025)
Table 69. Global Neuromyelitis Optic Spectrum Disorder Drugs Price (US$/Unit) by Application (2026-2031)
Table 70. Pfizer Company Information
Table 71. Pfizer Description and Business Overview
Table 72. Pfizer Neuromyelitis Optic Spectrum Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Pfizer Neuromyelitis Optic Spectrum Disorder Drugs Product
Table 74. Pfizer Recent Developments/Updates
Table 75. Fresenius Company Information
Table 76. Fresenius Description and Business Overview
Table 77. Fresenius Neuromyelitis Optic Spectrum Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Fresenius Neuromyelitis Optic Spectrum Disorder Drugs Product
Table 79. Fresenius Recent Developments/Updates
Table 80. Teva Company Information
Table 81. Teva Description and Business Overview
Table 82. Teva Neuromyelitis Optic Spectrum Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Teva Neuromyelitis Optic Spectrum Disorder Drugs Product
Table 84. Teva Recent Developments/Updates
Table 85. Sandoz Company Information
Table 86. Sandoz Description and Business Overview
Table 87. Sandoz Neuromyelitis Optic Spectrum Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Sandoz Neuromyelitis Optic Spectrum Disorder Drugs Product
Table 89. Sandoz Recent Developments/Updates
Table 90. Intas Company Information
Table 91. Intas Description and Business Overview
Table 92. Intas Neuromyelitis Optic Spectrum Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Intas Neuromyelitis Optic Spectrum Disorder Drugs Product
Table 94. Intas Recent Developments/Updates
Table 95. Gyjtrs Company Information
Table 96. Gyjtrs Description and Business Overview
Table 97. Gyjtrs Neuromyelitis Optic Spectrum Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Gyjtrs Neuromyelitis Optic Spectrum Disorder Drugs Product
Table 99. Gyjtrs Recent Developments/Updates
Table 100. NANG KUANG Company Information
Table 101. NANG KUANG Description and Business Overview
Table 102. NANG KUANG Neuromyelitis Optic Spectrum Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. NANG KUANG Neuromyelitis Optic Spectrum Disorder Drugs Product
Table 104. NANG KUANG Recent Developments/Updates
Table 105. Tianjin Kingyork Company Information
Table 106. Tianjin Kingyork Description and Business Overview
Table 107. Tianjin Kingyork Neuromyelitis Optic Spectrum Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Tianjin Kingyork Neuromyelitis Optic Spectrum Disorder Drugs Product
Table 109. Tianjin Kingyork Recent Developments/Updates
Table 110. Baxter Company Information
Table 111. Baxter Description and Business Overview
Table 112. Baxter Neuromyelitis Optic Spectrum Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Baxter Neuromyelitis Optic Spectrum Disorder Drugs Product
Table 114. Baxter Recent Developments/Updates
Table 115. CSL Company Information
Table 116. CSL Description and Business Overview
Table 117. CSL Neuromyelitis Optic Spectrum Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. CSL Neuromyelitis Optic Spectrum Disorder Drugs Product
Table 119. CSL Recent Developments/Updates
Table 120. Grifols Company Information
Table 121. Grifols Description and Business Overview
Table 122. Grifols Neuromyelitis Optic Spectrum Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Grifols Neuromyelitis Optic Spectrum Disorder Drugs Product
Table 124. Grifols Recent Developments/Updates
Table 125. Octapharma Company Information
Table 126. Octapharma Description and Business Overview
Table 127. Octapharma Neuromyelitis Optic Spectrum Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Octapharma Neuromyelitis Optic Spectrum Disorder Drugs Product
Table 129. Octapharma Recent Developments/Updates
Table 130. CBOP Company Information
Table 131. CBOP Description and Business Overview
Table 132. CBOP Neuromyelitis Optic Spectrum Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. CBOP Neuromyelitis Optic Spectrum Disorder Drugs Product
Table 134. CBOP Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Neuromyelitis Optic Spectrum Disorder Drugs Distributors List
Table 138. Neuromyelitis Optic Spectrum Disorder Drugs Customers List
Table 139. Neuromyelitis Optic Spectrum Disorder Drugs Market Trends
Table 140. Neuromyelitis Optic Spectrum Disorder Drugs Market Drivers
Table 141. Neuromyelitis Optic Spectrum Disorder Drugs Market Challenges
Table 142. Neuromyelitis Optic Spectrum Disorder Drugs Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
Table 146. Authors List of This Report
List of Figures
Figure 1. Product Picture of Neuromyelitis Optic Spectrum Disorder Drugs
Figure 2. Global Neuromyelitis Optic Spectrum Disorder Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Neuromyelitis Optic Spectrum Disorder Drugs Market Share by Type: 2024 & 2031
Figure 4. Glucocorticoids Product Picture
Figure 5. Immunotherapies Product Picture
Figure 6. Other Product Picture
Figure 7. Global Neuromyelitis Optic Spectrum Disorder Drugs Market Value by Application (2020-2031) & (US$ Million)
Figure 8. Global Neuromyelitis Optic Spectrum Disorder Drugs Market Share by Application: 2024 & 2031
Figure 9. Acute Attack
Figure 10. Remission Prophylactic Treatment
Figure 11. Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Neuromyelitis Optic Spectrum Disorder Drugs Market Size (2020-2031) & (US$ Million)
Figure 13. Global Neuromyelitis Optic Spectrum Disorder Drugs Sales (2020-2031) & (K Units)
Figure 14. Global Neuromyelitis Optic Spectrum Disorder Drugs Average Price (US$/Unit) & (2020-2031)
Figure 15. Neuromyelitis Optic Spectrum Disorder Drugs Report Years Considered
Figure 16. Neuromyelitis Optic Spectrum Disorder Drugs Sales Share by Manufacturers in 2024
Figure 17. Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue Share by Manufacturers in 2024
Figure 18. Global 5 and 10 Largest Neuromyelitis Optic Spectrum Disorder Drugs Players: Market Share by Revenue in Neuromyelitis Optic Spectrum Disorder Drugs in 2024
Figure 19. Neuromyelitis Optic Spectrum Disorder Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 20. Global Neuromyelitis Optic Spectrum Disorder Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 21. North America Neuromyelitis Optic Spectrum Disorder Drugs Sales Market Share by Country (2020-2031)
Figure 22. North America Neuromyelitis Optic Spectrum Disorder Drugs Revenue Market Share by Country (2020-2031)
Figure 23. United States Neuromyelitis Optic Spectrum Disorder Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 24. Canada Neuromyelitis Optic Spectrum Disorder Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Europe Neuromyelitis Optic Spectrum Disorder Drugs Sales Market Share by Country (2020-2031)
Figure 26. Europe Neuromyelitis Optic Spectrum Disorder Drugs Revenue Market Share by Country (2020-2031)
Figure 27. Germany Neuromyelitis Optic Spectrum Disorder Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. France Neuromyelitis Optic Spectrum Disorder Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. U.K. Neuromyelitis Optic Spectrum Disorder Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. Italy Neuromyelitis Optic Spectrum Disorder Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Russia Neuromyelitis Optic Spectrum Disorder Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Asia Pacific Neuromyelitis Optic Spectrum Disorder Drugs Sales Market Share by Region (2020-2031)
Figure 33. Asia Pacific Neuromyelitis Optic Spectrum Disorder Drugs Revenue Market Share by Region (2020-2031)
Figure 34. China Neuromyelitis Optic Spectrum Disorder Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Japan Neuromyelitis Optic Spectrum Disorder Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. South Korea Neuromyelitis Optic Spectrum Disorder Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. India Neuromyelitis Optic Spectrum Disorder Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Australia Neuromyelitis Optic Spectrum Disorder Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. China Taiwan Neuromyelitis Optic Spectrum Disorder Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Indonesia Neuromyelitis Optic Spectrum Disorder Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Thailand Neuromyelitis Optic Spectrum Disorder Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Malaysia Neuromyelitis Optic Spectrum Disorder Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Latin America Neuromyelitis Optic Spectrum Disorder Drugs Sales Market Share by Country (2020-2031)
Figure 44. Latin America Neuromyelitis Optic Spectrum Disorder Drugs Revenue Market Share by Country (2020-2031)
Figure 45. Mexico Neuromyelitis Optic Spectrum Disorder Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Brazil Neuromyelitis Optic Spectrum Disorder Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Argentina Neuromyelitis Optic Spectrum Disorder Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Middle East and Africa Neuromyelitis Optic Spectrum Disorder Drugs Sales Market Share by Country (2020-2031)
Figure 49. Middle East and Africa Neuromyelitis Optic Spectrum Disorder Drugs Revenue Market Share by Country (2020-2031)
Figure 50. Turkey Neuromyelitis Optic Spectrum Disorder Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Saudi Arabia Neuromyelitis Optic Spectrum Disorder Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. UAE Neuromyelitis Optic Spectrum Disorder Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Global Sales Market Share of Neuromyelitis Optic Spectrum Disorder Drugs by Type (2020-2031)
Figure 54. Global Revenue Market Share of Neuromyelitis Optic Spectrum Disorder Drugs by Type (2020-2031)
Figure 55. Global Neuromyelitis Optic Spectrum Disorder Drugs Price (US$/Unit) by Type (2020-2031)
Figure 56. Global Sales Market Share of Neuromyelitis Optic Spectrum Disorder Drugs by Application (2020-2031)
Figure 57. Global Revenue Market Share of Neuromyelitis Optic Spectrum Disorder Drugs by Application (2020-2031)
Figure 58. Global Neuromyelitis Optic Spectrum Disorder Drugs Price (US$/Unit) by Application (2020-2031)
Figure 59. Neuromyelitis Optic Spectrum Disorder Drugs Value Chain
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
